iBio (IBIO) Raw Materials (2021 - 2022)

iBio (IBIO) posted quarterly Raw Materials of $3.9 million for Q2 2022, up 18.67% quarter-over-quarter from $3.3 million in Q1 2022.

iBio (IBIO) Raw Materials (2021 - 2022) Analysis & Trends

iBio (IBIO) has reported Raw Materials for 2 consecutive years, with $3.9 million the latest figure, recorded in Q2 2022.

In Q2 2022, Raw Materials changed N/A year-over-year to $3.9 million; the TTM figure through Jun 2022 stood at $3.9 million (changed N/A YoY), while the FY2022 annual figure was $3.9 million, changed N/A from the prior year.
Raw Materials advanced to $3.9 million in Q2 2022 per IBIO's latest filing, from $3.3 million in the prior quarter.
Across five years, Raw Materials topped out at $3.9 million in Q2 2022 and bottomed at $487000.0 in Q3 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.77 Bn	131.91 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.74 Bn	78.75 Bn	3.93 Bn
3	Argenx Se	65.36 Bn	60.17 Bn	1.37 Bn
4	Moderna	59.60 Bn	54.47 Bn	52.00 Mn
5	BeOne Medicines	42.10 Bn	37.00 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.80 Bn	28.49 Bn	992.69 Mn
7	BioNTech SE	28.13 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.54 Bn	26.38 Bn	358.27 Mn
9	Royalty Pharma	27.31 Bn	26.47 Bn	-
10	iBio	173.42 Mn	173.42 Mn	-

Download Data